The effects of the treatment of 
INTRODUCTION
The effects of a new generation ruthenium(Ill) complex, Na[trans-RuCl4(DMSO)lm], are different from those of cisplatin in that, unlike cisplatin that is equally active on primary tumor growth and lung colonies, Na[trans-RuCl4(DMSO)lm] is markedly effective only on spontaneous metastases (1) (2) (3) . The selectivity of Na[trans-RuCl4(DMSO)lm] on lung metastases is marked also on advanced metastases and accounts for a significant prolongation of host's survival time, particularly in the experiments in which drug treatment is associated with surgical removal of primary tumor. This effect is not associated with any residual effect on primary tumor cells after treatment discontinuation whereas it tends to reduce the metastatic ability of the same tumor (3) .
Either by means of vivo-vivo bioassays or by microscopical examination it appears that the growth of lung tumors is markedly reduced whereas the growth of the i.m. primary tumor is much less affected and histologically not detectable. These effects account for the prolongation of the survival time and for the cure rate observed and highlight the pharmacological properties of this compound for the control of solid tumor metastases, an effect that was shown to be similarly exerted also on advanced tumor metastases (4, 5) . Metastases represent the greatest obstacle to cures after surgery and/or radiotherapy in that they often show a low chemosensitivity to the available anticancer drugs (6) . The lack of success derives from the fact that tumor metastases are always treated with drugs that have been specifically developed by studying their activity in reducing primary tumor growth rather than by examining their efficacy on the more selective metastatic population (7) . The aim of the present investigation was that of examining the cumulative effects of repeated treatments for several transplant generations on primary tumor growth and lung metastasis formation using the MCa mammary carcinoma of CBA mouse. Tumor treatment will be performed in vivo either in mice immunesuppressed by DTIC or in intact hosts. Parallelly, in vitro treatments of TLX5 lymphoma cells for up to 13 transplant generations will be performed to ascertain the possible occurrence of chemical xenogenizing effects, similar to those caused by triazeno derivatives and nitrosoguanidine derivatives (8) (9) (10) For the experimental purposes, the tumor was collected from the peritoneal cavity of donor mice inoculated one week before, and washed twice with PBS. in vitro-in vivo bioassays. Tumor cell suspensions of TI_X5 lymphoma (10 s cells/ml) were kept in vitro at 37C for 60 rain under shaking in tissue culture tubes with 1.9 ml of PBS containing antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin) to which were added 100 ml PBS containing the test compound for a final volume of 1.5 ml. At the end of the incubation, aliquots of 0.1 ml were injected i.p. into intact syngenic CBA mice of which survival time was recorded. Brain metastases. The determination of the occurrence of leukemic brain involvement was performed by means of a vivo-vivo bioassay. Briefly, whole brains of mice transplanted with TI_X5 lymphoma cells one week before, were aseptically removed after killing of the animal by cervical dislocation. Brains were subsequently transplanted s.c. in the flank of intact syngenic CBA mice by means of a sterile syringe with a 19x21 needle. The survival time of the transplanted mice gave an indirect measure of the amount of TLX5 lymphoma cells present in the transplanted brains (12, 13) . Cytofluorimetric analys!s. Propidium iodide staining was performed according to the procedure described by Krishan (14) . Orange acridine staining was performed according to the methods of Dar-zynkiewicz (15 Taken together these observations stress the already reported lack of cytotoxicity of Na[transRuCI(DMSO)Im] for tumor cells and suggest that the interaction of this compound with tumor cells does not induce resistence to the antimetastastic effect. Conversely it seems that the selection of a cell population with higher sensitivity to its antimetastastic action is unrelated to an appreciable modification of tumor take and growth in the syngenic hosts.
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